Peripheral neurotoxicity occurs in approximately 40 percent of previously untreated cancer patients who receive chemotherapy regimens containing taxane. Because the effects of this therapy may limit treatment for a significant percentage of patients, it is essential for researchers to have access to study models that can mimic taxane toxicity. Charles River conducts contract studies in an established animal model of neurotoxicity to test the efficacy of novel therapeutics.